Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 153Neoplasm Metastasis 146Breast Neoplasms 143Neoplasms 142Colorectal Neoplasms 135Recurrence 104Ovarian Neoplasms 100Pancreatic Neoplasms 81Lung Neoplasms 81Multiple Myeloma 80Advanced Solid Tumor 80Advanced Solid Tumors 74Prostatic Neoplasms 73Stomach Neoplasms 72Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 67Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 63Triple Negative Breast Neoplasms 57Myelodysplastic Syndromes 54Lymphoma, B-Cell 53Endometrial Neoplasms 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Glioma 51Lymphoma 49Brain Neoplasms 46Hematologic Neoplasms 44Carcinoma, Renal Cell 44

Interventions

sodium thiosulfate 1Platinum 1Magnetic Resonance Spectroscopy 1Hearing 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Hearing Loss × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡